alvimopan	pre–alvimopan	Time to regular diet	12369	12510	Time to regular diet was significantly longer in the pre–alvimopan cohort at 7.1 days compared to 4.8 days in the treatment group (p = 0.020)
alvimopan	control	length of stay (LOS)	919	1087	Patients who received alvimopan experienced a shorter length of stay (LOS) versus those in who did not receive alvimopan (10.5 vs. 8.6 days, p = 0.005, 95% CI 0.6–3.3).
alvimopan	pre–alvimopan	disposition of patients from the OR to the intensive care unit	11629	11760	There was increased disposition of patients from the OR to the intensive care unit in the alvimopan group (44% vs. 66%, p = 0.048).
alvimopan	pre–alvimopan	Utilization of total parenteral nutrition	12119	12252	Utilization of total parenteral nutrition was higher in the pre–alvimopan group (38.8% pre–alvimopan 20.6% vs. alvimopan, p = 0.010).
alvimopan	control	Costs	1184	1300	Costs were significantly lower in the alvimopan group than the control groups (2012 USD 32,443 vs. 40,604 p <0.001).
alvimopan	pre–alvimopan	use of robotic technique	11761	11866	Additionally, use of robotic technique increased markedly in the alvimopan group (8% vs. 25%, p = 0.030).
alvimopan	pre–alvimopan	Time to regular diet	12369	12511	Time to regular diet was significantly longer in the pre–alvimopan cohort at 7.1 days compared to 4.8 days in the treatment group (p = 0.020).
